{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"6.9","value":"3.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"The distribution of duration of response (CR or PR) will be estimated using the method of Kaplan-Meier. Complete response (CR): target nodes/nodal masses must regress to \\<=1.5 cm in longest transverse diameter (LDi). Partial response (PR): \\>= 50% decrease in sum of the product of the diameters (SPD) of up to 6 target measurable nodes and extranodal sites.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 240 mg nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive 480 mg nivolumab IV over 60 minutes on day 1 of cycle 9. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Nivolumab)"}],"paramType":"MEDIAN","populationDescription":"Participants who achieved a response are included in this analysis.","reportingStatus":"POSTED","timeFrame":"Up to 390 days","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}